CMS’s Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks Read more about CMS’s Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks
Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act Read more about Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act
The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting Read more about The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting
Unanswered Questions and Unintended Consequences of State Prescription Drug Affordability Boards Read more about Unanswered Questions and Unintended Consequences of State Prescription Drug Affordability Boards
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value Read more about Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
CMS Proposes Changes to Medicaid Best Price Read more about CMS Proposes Changes to Medicaid Best Price